GenSci holds exclusive Chinese rights to Camcevi, covering central precocious puberty, premenopausal breast cancer, and ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China's National ...

Foresee Pharmaceuticals was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China'sNational Medical Products Administration (NMPA) has approved the ...

Foresee Pharmaceuticals announces China NMPA grants marketing authorization for Camcevi 42 mg to treat advanced prostate cancer: Taipei Tuesday, October 13, 2026, 11:00 Hrs [IST] ...

In addition to the NMPA's approval of CAMCEVI ® 42 mg for advanced prostate cancer described above, GenSci submitted a ...

China approved CAMCEVI 42 mg for advanced prostate cancer, with GenSci responsible for commercialization under an exclusive ...

Advanced prostate cancer is a form of prostate cancer that has spread or progressed beyond the prostate gland and has often requires long-term hormone-based treatment to slow disease growth. CAMCEVI ...

Foresee Pharmaceuticals (6576.TWO) said it was notified by licensing partner, Changchun GeneScience Pharmaceutical, that China's National Medical Products Administration has approved the Marketing ...

ChangchunHigh-Tech Industry's (SHE:000661) unit, Changchun GeneScience Pharmaceutical, received approval for the clinical ...

Anaerobox IV型厌氧培养箱由美国Gene Science于2014年4月发布，具备同时运行四个独立程序的能力，支持教学、科研和临床样本的厌氧及微氧培养。其温度控制范围为室温+5℃至70℃，温度均匀性为±0.5 ...